News
Videos
Conferences
Events
Resources
Subscribe

|Videos|September 27, 2017

Immunotherapy in Bladder Cancer

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Image of bladder.

Basics of Squamous Cell Bladder Cancer

November 25th 2025

FDA sign image

AVZO-103 Wins FDA Designation for Previously Treated Urothelial Cancer

November 25th 2025

Image of "FDA"

FDA Approves Keytruda and Padcev for Muscle Invasive Bladder Cancer

BySpencer Feldman

November 21st 2025

leading oncology experts

Cancer Experts Share Emerging Treatments Patients Should Know in 2026

November 12th 2025

Trial data showed a 62% complete response rate at 6 months with detalimogene coraplasmid among patients with high-risk, BCG-unresponsive bladder cancer.

Detalimogene Shows 62% Response Rate in Bladder Cancer Trial

BySpencer Feldman

November 12th 2025

Trending on CURE

FDA Approves Imfinzi Plus Chemo in GC/GEJC

How New Therapies Are Changing the Game for Small Cell Lung Cancer

Sac-TMT Combo Shows Benefit in Advanced Lung Cancer Treatment

How Vaccines Can Partner With Immunotherapy to Treat Lung Cancer

Expert Explains Recent Advances in Early Stage Lung Cancer Surgery

© 2025 MJH Life Sciences^®

All rights reserved.